NASD · Healthcare · Medical Devices · USA
ClearPoint Neuro Inc is a micro cap company (market value under $300 million) in the Medical Devices industry.
ClearPoint Neuro manufactures guidance systems and therapeutic devices for neurosurgery, including platforms for brain procedures with MRI navigation and laser ablation technology. Through its acquisition of IRRAS Holdings, the company also offers fluid management solutions for neurocritical care. Additionally, ClearPoint provides consulting services to pharmaceutical partners developing therapies for brain delivery.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the ClearPoint Neuro Inc stock.
Overvalued: intrinsic value $1.23 per share, market price $7.86, margin of safety -539.1% (as of 2026-11-17).
A 0.9x revenue multiple, discounted for its losses, values the shares at $1.23; the price of $7.86 is 539% above that value.
16 more funds hold it; the full list is part of the paid plan.
All 140 Medical Devices stocks
52 more in this industry show a wider margin of safety.
CLPT is overvalued (as of the 2026-11-17 close). A 0.9x revenue multiple, discounted for its losses, values the shares at $1.23; the price of $7.86 is 539% above that value.
$1.23 per share (as of the 2026-11-17 close), against a market price of $7.86. That is a margin of safety of -539.1%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.